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Comparison of loop diuretics in patients with chronic renal insuffi-
ciency. Furosemide and bumetanide share a number of characteristics
including reduced natriuretic effects in azotemic patients. It has been
presumed that this condition affects each drug equally, Previous stud-
ies, however, suggest dissimilar pathways of delivery to their sites of
action. Though not rigorously tested, this potential disparity might
cause them to differ when used in azotemia. We, therefore, assessed the
pharmacokinetic and pharmacodynamic characteristics of intravenously
administered furosemide and bumetanide in ten adult patients with
stable, chronic renal insufficiency (mean creatinine clearance = 14.1
2.0 mI/mm/I .73 m2) in a randomized, cross—over study during con-
trolled sodium intake. Our goals were to assess differences in diuretic
effectiveness and in so doing to determine the dose required to produce
a maximal response. The mean diuretic doses of 172 and 4.3 mg for
furosemide and bumetanide, respectively (ratio = 40:1) were sufficient
to produce a maximum response. Despite similarities in maximal
fractional excretion of sodium (18.2 2.6% with furosemide vs. 19.4
4.5% with bumetanide, P = 0.687) demonstrating an equal tubular
responsiveness to both drugs, overall response as quantified by cumu-
lative natriuresis in the initial eight hour period was 52% greater with
furosemide (108 17 vs. 71 7 mEq; P = 0.042). The difference in total
excreted sodium was accounted for by a preserved nonrenal clearance
of bumetanide (113 12 compared to 53 5 mI/mm for furosemide, P
= 0.001) which resulted in relatively less bumetanide in serum available
to be delivered into the urine. Thus, while renal clearances were
numerically similar (6 1 vs. 7 1 mI/mm for furosemide and
bumetanide, respectively, P = 0.549), the percentage of the bumetanide
dose excreted in the urine during the initial eight hours was 42% less
than furosemide (5.2 1.0% vs. 9.0 1.8%, P = 0.021). In summary,
patients with stable, severe chronic renal insufficiency have a greater
cumulative sodium excretion after intravenous furosemide compared to
a dose of bumetanide determined to be equipotent in patients with
normal renal function, The mechanism of the disparity between the two
diuretics was explained by differences in nonrenal clearance. The
clinical implications of these findings are that comparable patients
require a dose ratio of furosemide to bumetanide of 20:1 to attain equal
effects in contrast to a ratio of 40:1 in patients with preserved renal
function.
Furosemide and bumetanide are high ceiling or loop diuretics
used commonly in the treatment of edematous states. Under
normal conditions, these diuretics share many pharmacokinetic
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and pharmacodynamic properties [1—4]. Both drugs owe their
major diuretic activity to inhibition of active solute reabsorption
by the cells of the thick ascending limb of Henle's loop [5, 6].
Furosemide is known to reach its urinary (luminal) site of action
via secretion by the organic acid transport system of the
proximal tubule [7, 8]. This pathway is competitively inhibited
by endogenous organic acids which accumulate in chronic renal
insufficiency (CR1) and impair diuretic secretion [9—11]. To
circumvent this inhibitory effect, large doses of furosemide are
routinely administered to increase the serum concentration,
thereby providing sufficient delivery of drug into the urine. The
potential of such a strategy is, however, an increased risk for
extrarenal toxicity. Alternatively, if a loop diuretic reaches its
site of action by a pathway other than the organic—acid secre-
tory pump, it might theoretically be less subject to the condi-
tions causal of resistance in CR!. Such an agent might permit
doses that more closely approximate those required under
non-azotemic conditions. Bumetanide, although active in the
same nephron segment as furosemide, may qualitatively differ
in its mechanism of access to its site of action as a result of its
different chemical characteristics [12]. Hence, there has been
considerable speculation as to differences in response between
these two drugs raising questions as to settings in which use of
one may be preferable to the other.
Comparison of furosemide and bumetanide in the same
patients with CR1 by the systematic assessment of pharmaco-
kinetic and pharmacodynamic determinants of diuretic re-
sponse has not heretofore been pursued. Such an evaluation is
the only unequivocal method by which their diuretic effective-
ness can be compared. For these reasons, in a randomized
cross—over fashion we compared the pharmacokinetic and
pharmacodynamic determinants of diuretic response after intra-
venously administered furosemide and bumetanide in patients
with stable, severe CR1 on a controlled sodium intake. Both
agents successfully produced a diuresis and we were thus able
to estimate the dose of each required to elicit a maximal
response. However, the cumulative natriuresis following furo-
semide was significantly greater than with bumetanide, a result
accounted for by relatively greater amounts of furosemide
delivered to its urinary site of action.
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Table 1. Patient characteristics
Bumetan-
Subject
number
Age
yrs
Race!
sex
Weight
kg
Cc- ml!
min!1.73m2
Furosemide
dose mg
ide dose
mg Diagnosesa
Concomitant
medications
1 61 W/M 104.5 16 120 3 Hypertension
Gout
Angina
Isosorbide
dinitrate
Diltiazem
Gemfibrozil
Allopurinol
Nitroglycerine
2 57 W!M 74.2 16 160 4 Polycystic kidney
disease
Hypertension
Gout
Osteoarthritis
Nadolol
Minoxidil
Allopurinol
3 62 W/M 77.3 12 120 3 Medullary sponge
kidney
Nephrolithiasis
Allopurinol
4 50 W!M 55.6 27 120 3 Diabetes mellitus
Hypertension
COPD
Clonidine
Theophylline
Glyburide
5 65 W!M 74.8 9 120 3 Diabetes mellitus
Hypertension
Insulin
Clonidine
6 59 NAJM 74.0 16 160 4 Diabetes mellitus
CAD
Insulin
Nifedipine
Isosorbide
dinitrate
Digoxin
7 34 B!F 102.6 12 160 4 Hypertension
Analgesic abuse
Clonidine
Cephalexin
8 40 B/F 86.8 3 600 15 Lupus nephritis Hydralazine
9 65 B!M 60.9 11 80 2 Hypertension Nifedipine
10 54 B!M 48.0 10 80 2 Hypertension None
COPD denotes chronic obstructive pulmonary disease; CAD denotes coronary artery disease.
Methods
Study protocol
Ten adult patients (Table 1) with a mean creatinine clearance
(Car) of 14.3 2.0 ml/minll .73 m were admitted to the General
Clinical Research Center after signing an informed consent.
These patients had demonstrated stable renal impairment over
the preceeding months and were without nephrotic range pro-
teinuria or decompensated edema—forming states.
At the time of admission, all diuretics were discontinued
(other medications were maintained) and a 30 mEq/day sodium,
60 to 80 mEq/day potassium diet was begun. This level of
sodium intake was chosen based on prior studies from our
laboratory in similar patients indicating this value approximated
the obligate sodium loss. Consequently, we were able to attain
balance conditions but could still insure sufficient sodium
restriction that maintenance diuretic therapy could be stopped.
Patients were monitored with daily weights, serum and 24-hour
urinary electrolytes and Ccr with sodium balance reached by
day 6. On the morning of day 6, the patients were randomized
to receive either furosemide or bumetanide by a constant
intravenous infusion over 15 minutes. Each patient received a
dose equivalent to his/her normal individual oral dose (such as,
a patient receiving 160 mg bid of furosemide would receive 160
mg). The dose of bumetanide was 1/40th that of furosemide to
account for the difference in potency between drugs as derived
from data in normal subjects [13, 14]. On the morning of diuretic
Table 2. Control indices before each study phase (mean 5EM)
Furosemide Bumetanide P Value
Weight kg
Na excretion mEq/24 hr
FENa %
Ccr mI/mm
75.9 5.8
26.6 4.3
1.5 0.5
16.9 2.6
75.7 5.8
20.1 4.3
1.2 0.3
13.7 1.8
0.369
0.373
0.317
0.078
administration, each patient skipped breakfast and intravenous
catheters were placed in each forearm for administration of
drug as well as replacement fluids. Urinary and insensible fluid
losses (1 mI/mm) were replaced with 0.45% NaCI infused at a
constant rate to match volume loss during the preceding collec-
tion interval. Serum samples for measurement of electrolytes,
creatinine and drug concentrations were obtained at —30, + 15,
30, 45, 60, 90, 120, 180, 240, 360, 480 and 1440 minutes. Urine
samples for measurement of volume, electrolyte, creatinine and
drug concentrations were obtained by spontaneous hourly
voiding from —1 to +6 hours and specimens were pooled in the
six to eight hour as well as eight to 24 hour time periods.
Following this phase of the protocol, the patients were
maintained on the same diet for an additional three days with
monitoring as before. Sodium balance was again achieved by
day 10 (Table 2) which constituted the second study period. The
protocol was repeated in a fashion identical to day 6 except
administration of the alternative drug.
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Fig. 1. Cumulative 8 hour sodium excretion caused by furosernide and
bumetanide (A). Fraction of the dose appearing in the urine during the
identical time period (B).
Chemical determinations
Electrolytes were measured with ion specific electrodes and
creatinine with the Jaffe reaction by autoanalyzer (Beckman
ASTRA 8, Beckman Instruments, Fullerton, California, USA).
Serum and urinary diuretic concentrations were measured by
HPLC as previously described [8, 15]. Briefly for furosemide:
metolazone (internal standard) was added to serum and urine
samples with adjustment to pH 3.7 by addition of 1.2 M acetate.
Dichloromethane was then added, the sample vortexed, and the
aqueous phase removed via aspiration. The remaining organic
layer was dried under nitrogen and low heat. The samples were
reconstituted in methanol and injected onto two sequential C18
radial compression columns of 10 micron particle size. The
columns were eluted with 34% acetonitrile in 0.01 M acetate
buffer (adjusted to pH 3.3) at a flow rate of 1.0 mllmin using a
Perkin Elmer Series III liquid chromatograph (Perkin Elmer,
Norwalk, Connecticut, USA). Drug was detected with a Perkin
Elmer 650-lOS fluorescence spectrophotometer with excitation
and emission wavelengths of 344 and 410 nm, respectively.
For bumetanide, aliquots of urine and serum samples plus the
internal standard, 4-benzyl-3-n-butylamino-5-sulphamoyl ben-
zoic acid, were adjusted to pH 1.7 with 1.0 M phosphate buffer.
Samples were then extracted and reconstituted as with furose-
mide. These samples were injected onto a C18 Zorbax steel
column which was then eluted at a flow rate of 1.0 mI/mm with
45% acetonitrile in 0,01 M acetate buffer adjusted to pH 3.3.
Drug was detected by fluorescence utilizing excitation and
emission wavelengths of 338 and 440 nm, respectively.
A standard curve was determined with each diuretic assay,
the correlation coefficient (r2) of which always exceeded 0.990.
Data analysis
The pharmacokinetic parameters for furosemide and bumet-
anide were determined in standard fashion. The terminal elim-
ination rate constant was calculated by linear least—squares
regression. Clearance was calculated as dose/AUC where AUC
represents the area under the curve of serum concentration
versus time. In turn, AUC was quantified by the trapezoidal
Furosemide Bumetanide P Value
Diuretic clearance mi/mm
Total 59 5 120 12 0.002
Renal 6 1 7 1 0.549
Nonrenal 53 5 113 12 0.001
Half—life mm 157 15 99 6 0.005
Fraction of diuretic 9.0 1.8 5.2 1.0 0.021
excreted unchanged
during hours 0 to 8, %
rule with extrapolation from the last measured serum concen-
tration to infinity using the elimination rate constant. Renal
clearance was calculated as urinary drug excretion over 24
hours divided by the serum AUC to 24 hours. Nonrenal
clearance was the difference between total and renal clearance.
For pharmacodynamic analyses, the mean of individual data
was used to derive an average relationship between urinary or
serum amounts of the diuretics with response. This relationship
defined sigmoid-shaped dose—response curves which were an-
alyzed by the ALLFIT computer program fitting the data to a
standard format [16]:
a— dY= +d
1 + (-)b
The model used is the four parameter logistic equation where Y
and X are response (fractional excretion of sodium [FENa])
and dose (diuretic excretion rate or serum concentration) re-
spectively and a, b, c, and d are the four derived parameters: a
= FENa (%) at zero dose, b = slope factor (unitless parame-
ter), c = ED50 or dose causing half—maximal change in response
(sg/min), and d = FENa (%) at infinite dose or the maximal
response.
Comparisons of paired data were made using the Student's
t-test with a P value < 0.05 considered significant. Data are
expressed as the mean standard error of the mean.
Results
The control indices of weight, 24-hour sodium excretion,
baseline FENa and Cç (Table 2) were similar between groups,
suggesting that sodium balance had been achieved before each
study. Figure 1 shows the cumulative sodium excretion follow-
ing each diuretic in the initial eight hours after dosing as well as
the fraction of the diuretic dose excreted into the urine. This
time period encompasses the interval wherein the total re-
sponse to each diuretic occurred and greater than 90% of the
amount of each drug eventually recovered in the urine was
excreted. During this time, cumulative natriuresis after furose-
mide exceeded that for bumetanide by 52% (P = 0.042) and
relative to dose, 73% more furosemide appeared in the urine (P
= 0.021). There were no significant differences between diuret-
ics in terms of potassium excretion or urinary volume (25 5
vs. 24 4 mEq, P = 0.512; and 1.4 0.2 vs. 1.3 0.2 liter, P
= 0.283; for furosemide and bumetanide, respectively).
Table 3 presents the pharmacokinetic data for the two diuret-
ics in these patients with CR1. The total clearance of bumeta-
LU
a)
Table 3. Pharmacokinetic parameters for furosemide and bumetanide
in patients with CR1 (mean 5EM)a
a)C
C
a)
a)
U
a)
a)0
0
C0
C.)
a)
U-
B P=0.021
24.0
20.0
16.0
8.0
12.0
4.0
a Data from the 24-hour sampling period were used to derive clear-
ance and half—life values
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Table 4. Serum concentrations (sg/m1) of furosemide and bumetanide and their ratio (mean SEM)
Time mm
15 30 45 60 90 120 180 240 360 480 1440
Furosemide (F)
Bumetanide (B)
Ratio F/B
19.1
0.50
38
14.1
0.26
54
11.8
0.20
59
10.1
0.15
67
8.3
0.12
69
7.0
0.09
78
5.4
0.06
90
4.2
0.04
105
2.7
0.02
135
1.8
0.01
180
0.09
0.004
23
+
z
wU-
25.0
20.0
15.0
10.0
5.0
0
0.10 1.0
UV diuretic, g/min
nide exceeded that of furosemide by 100% (P = 0.002) while
both diuretics had a numerically similar rate of renal clearance
(P = 0.549). This difference in total clearance, therefore, was
due entirely to a lower nonrenal clearance rate for furosemide
(P = 0.001) which in turn resulted in an increasingly greater
ratio of furosemide to bumetanide serum concentrations over
each subsequent time period (Table 4). The greater nonrenal
clearance of bumetanide compared to furosemide allowed a
more rapid elimination of bumetanide from the serum, resulting
in less drug available for entry into the urine. The reduced total
clearance of furosemide was reflected by a longer serum half—
life (Table 3) compared to bumetanide (P = 0.005).
For each diuretic, Figures 2 and 3 depict the dose—response
curves for urine and serum data, respectively, with the com-
puter—derived parameters for these sigmoid—shaped relation-
ships. Neither baseline nor peak FENa was significantly
different between diuretics. Urinary excretion rates and serum
diuretic concentrations were maximal during the first hour of
study and decreased over each subsequent time period. With
the exception of identical response values during the first two
hours of furosemide treatment, response to both diuretics
declined in parallel with either measure of dose. The dosage of
furosemide was sufficient to define to the upper plateau of its
dose—response curve with little difference between the ob-
served and the computer-derived value for maximal response
(parameter d). Similarly, the observed and calculated maximal
responses for bumetanide approximated; however, a clear
plateau did not occur as with furosemide. Though the similarity
Fig. 2. Dose—response curves for bumetanide
and furosemide constructed from the urinary
excretion of diuretic. The corresponding
_ computer derived values for parameters B, C
100.0 and D are shown. Parameter A is the baselineFENa during the control period (see text for
description of parameters).
of observed and derived maximal responses implies the ade-
quacy of our bumetanide dose in reaching the upper plateau of
response, the data are not definitive. Finally, calculations of
potency from the corresponding "c" values of the urine and
serum curves (that is, as the ratio of the amount of each drug
required to produce one—half the maximal change in response)
revealed bumetanide to be 44 times more potent than furose-
mide as determined from urine data and 65 times as potent when
measured from serum.
In summary, the doses of each diuretic administered in this
study were sufficient to define the maximal response. More-
over, the relative potencies of the two diuretics coupled with
the 40:1 ratio of infused doses used indicates that the difference
in cumulative response cannot be accounted for by a pharma-
codynamic mechanism and therefore is due to the pharmacoki-
netic differences discussed above.
Discussion
In these patients with CR1, the cumulative natriuresis over
the time which encompassed the duration of each diuretic's
effect was 52% greater after acute intravenous furosemide than
the response to a dose of bumetanide calculated to be equipo-
tent based on studies in normal subjects [13, 14] (Fig. 1). The
randomized, cross—over design and documentation of sodium
balance assured equivalent states for comparisons and estab-
lished that the difference in response is related to dissimilarities
in pharmacokinetics between the two diuretics. This somewhat
surprising inequality in cumulative natriuresis can be explained
10.0
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by a disparity in the effects of renal insufficiency on the
nonrenal elimination of the two diuretics.
Diuretic resistance may be caused by a variety of mecha-
nisms [17, 18]. Furosemide, a weak organic acid, requires
access into the urine to reach its site of action [7, 8]. This drug
is 95% to 98% bound to albumin in the serum of normal subjects
and thereby is subject to minimal glomerular filtration [3].
Access into the luminal fluid is achieved via secretion by the
organic acid secretory system of the proximal tubule. The
process is competitively inhibited by a number of endogenous
and exogenous acids [7—11, 19—21]. Accumulation of organic
acids during uremia impairs delivery of furosemide to its site of
action [9—11]. In addition, renal blood flow is reduced in CR1
which decreases delivery of the diuretic to its transporting site.
These combined effects reduce the amount of furosemide
delivered to its site of action. Supporting these mechanisms as
the sole cause for resistance to furosemide in patients with CR1
is the finding that, compared to subjects with normal renal
function, remnant nephrons respond normally when supplied
with adequate amounts of urinary furosemide [22, 23].
In patients with CR1, response to furosemide can be achieved
only by administering doses of drug which achieve high enough
serum concentrations to provide entry of sufficient amounts of
diuretic into the urine. A diuretic possessing structural charac-
teristics permitting access to its site of action via a pathway
unlike that of furosemide might result in a sufficient response in
patients with CR! utilizing doses effective under normal condi-
tions, Consequently, attempts have been made to find a diuretic
effective solely from the blood side of the tubule or one that
reaches a urinary site of action via a route not compromised in
CR!. Though studies of isolated segments of Henle's loop have
shown an intraluminal site of action of bumetanide [24], our
motivation for the comparison of these two diuretics came from
various other studies which have suggested that bumetanide
may have an effect from the blood side of the nephron or that it
reaches a urinary site of action by a pathway differing from
furosemide (vide infra).
Although bumetanide shares many pharmacokinetic and phar-
macodynamic properties with furosemide in normal subjects, it
has a number of potentially important differences. Bumetanide
contains a phenoxy group and lacks a halogen or pseudohalogen
(Fig. 4) felt necessary for furosemide's diuretic action [5].
Cl NHCH2 J[J
H2NO2S
'' COON
These differences could theoretically result in separate type and
perhaps location of receptor for bumetanide. In addition, bu-
metanide has three distinct pKa' s including one which is basic
(personal communication, I. Bekersky) which therefore might
allow for its secretion into the lumen by the organic base
transport system of the proximal tubule, a system presumably
not inhibited during CR! [9—11]. There has been disagreement
as to the route of access and requirements for entry of bumet-
anide into the urine. For example, studies have conflicted as to
effects of probenecid on secretion into the urine of bumetanide
and subsequent response [25—29]. In addition, a recent prelim-
inary study in isolated perfused whole rat kidneys found re-
sponse to bumetanide to be independent of tubular secretion,
raising the possibility that this diuretic reached its site of action
from the vascular side of the nephron [12]. As a result, it has
been postulated that the response to bumetanide could poten-
tially exceed that to furosemide during renal failure. Alterna-
tively, in CR1, a lower dose of bumetanide might be able to
cause the same effect as a large dose of furosemide. We were
surprised to observe the opposite result, namely, a greater
response to furosemide, though there is precedent for such an
observation in a previous study less controlled than ours [30].
Berg et al compared the effects of 250 mg of intravenous
furosemide with 8 mg of bumetanide given on consecutive days
to 12 patients with an average Cr of 6.3 ml/min and found the
greatest natriuresis following furosemide [30]. However, we felt
these results to be inconclusive because pharmacodynamic or
pharmacokinetic analyses were not utilized to determine the
cause of the difference in response, and sodium balance be-
tween study periods was not documented. Our patients were
initially allowed five days to equilibrate on the fixed sodium
JJ
25.0
20.0
15.0
10.0
5.0
0
Bumetarilde
0.01 0.10 1.0 10.0
Diuretic concentration, pg/mI
Fig. 3. Dose—response curves for bumetanide
and furosemjde constructed from the serum
100.0 diuretic concentrations. Format is as in
Figure 2.
H2NO2S
Bumetanide
Fig. 4. Structures of bumetanide and furosemide.
Furosemide
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intake followed by three days between studies. Urinary volume
and solute losses were replaced during the study to prevent
hypovolemia from blunting the true diuretic effect. It would
appear that sodium balance was achieved before each study
period as evidenced by the small differences between pre-study
control indices (Table 2).
To explore the mechanism for the discrepancy in cumulative
natriuresis, we compared dose—response curves for each drug
wherein response was measured as FENa to account for the
severe loss of nephron mass in these patients. Comparisons of
these curves demonstrated virtual identity of maximal re-
sponses to furosemide and bumetanide (Figs. 2 and 3), showing
the tubules to be equally responsive to both diuretics and
thereby eliminating a pharmacodynamic component (that is,
unequal tubular responsiveness) as causal of the differences in
cumulative natriuresis. These dose—response curves also dem-
onstrate that the difference in overall sodium excretion cannot
be accounted for by use of pharmacologically unequal doses of
diuretic since the dosing ratio of furosemide to bumetanide was
40:1 and the potency ratio calculated from the urinary dose—
response curves was 44:1.
From serum dose—response curves, bumetanide was calcu-
lated to be 65 times as potent as furosemide (Fig. 3). These data
imply that the difference in response between drugs was not due
to insufficient access of bumetanide to a receptor theoretically
reached from the blood. This finding, coupled with data from
studies in dogs [25, 26], as well as microperfusion of isolated
nephron segments [24], is evidence that bumetanide requires
delivery into the urine as the predominant, if not sole, prereq-
uisite for access to its site of action. Thus, in the current study,
we find no evidence for a pharmacodynamic mechanism for the
greater cumulative natriuresis caused by furosemide compared
to bumetanide, nor is there evidence for peritubular access of
bumetanide to a site of action.
Our findings must be explained by pharmacokinetic differ-
ences between the two diuretics. Our derived parameters
(Table 3) describing the disposition of both drugs are consistent
with values determined by others in CR1 [3 1—34]. Under normal
conditions, both drugs are cleared from the plasma at rates of
approximately 200 ml/min, and this elimination is divided
roughly equally between renal and nonrenal routes [2—3]. These
patients cleared bumetanide at a rate two times that of furose-
mide, such that for any given time period there was a relatively
greater serum concentration of furosemide compared to bumet-
anide (Table 4). This difference was not due to disproportionate
reductions in renal clearance since values for the two drugs
were similar and in each case were less than 10% of normal. In
contrast, the nonrenal clearance of bumetanide exceeded that
of furosemide by twofold and accounted for the entire differ-
ence in total clearance. The nonrenal clearance of bumetanide
was not increased but remained normal in patients with CR! as
opposed to a 50% reduction occurring with furosemide. The
exact reason for this difference is not clear.
Bumetanide is known to have a number of hepatic metabo-
lites compared to only a single glucuronide conjugate for
furosemide [35—41]. It is clear from our data that the metabolic
pathways normally followed for bumetanide are maintained in
patients with CR! while the nonrenal elimination of furosemide
in inhibited. The site of furosemide glucuronidation has not
been clearly identified. Though a hepatic site was initially
presumed, more recent data have implicated a renal origin [35,
42]. If true, it would seem logical that decreases in renal mass
would diminish this elimination pathway. Perhaps related is the
finding that probenecid diminishes the glucuronidation of furo-
semide but does not affect metabolism of bumetanide [8, 25]. It
is reasonable to presume that accumulated organic acids of
uremia also interfere with the uptake of furosemide to sites of
metabolism while not affecting bumetanide. Regardless of the
cause for the reduced nonrenal clearance of furosemide, the net
effect is relatively higher serum concentrations over time com-
pared to bumetanide, which provides for greater amounts of
drug available to reach the urinary site of action. This finding
accounts for the greater urinary excretion of furosemide and,
therefore, sodium following infusion of equipotent doses of
each diuretic.
The therapeutic implication of this study is that compared to
patients with normal renal function, those with CR1 require
proportionally greater doses of bumetanide than furosemide to
cause the same cumulative sodium excretion. With the diuretic
doses adninistered in our study, similar maximal values of
FENa occurred and in the case of furosemide, a clear upper
plateau of response was identified (Figs. 2 and 3). Though a
similar plateau was not clearly defined with bumetanide, mini-
mal differences were noted between the observed and comput-
er—derived maximal values (parameter d in Figs. 2 and 3),
implying that a slightly larger dose would have clearly delin-
eated an upper asymptote. Indeed, from our pharmacokinetic
and pharmacodynamic data, we are able to calculate that a dose
of bumetanide approximately 1/20th that of furosemide would
elicit equivalent cumulative effects in our patients. As such,
little is to be gained in patients comparable to these we studied
by administering single intravenous doses of bumetanide greater
than 6mg to 8 mg or 160mg of furosemide, since doing so would
merely result in modest prolongation of the amount of time
spent on the plateau portion of the dose—response curve.
Hence, the maximal response would not be significantly in-
creased and the concomitant rise in serum drug concentration
would only increase the risk of toxicity.
Our study lends support that bumetanide requires access into
the tubular lumen to exert its effects and confirms that in
patients with stable CR!, remnant nephrons are able to respond
normally when adequate amounts of diuretic are delivered to
the cells of the thick ascending limb of Henle's loop. Further-
more, these nephrons responded equally to furosemide and
bumetanide (pharmacodynamic equality). However, the cumu-
lative natriuresis from furosemide exceeded that for bumeta-
nide. This difference was accounted for by a preserved nonrenal
clearance of bumetanide, resulting in relatively less drug avail-
able to interact with its site of action (pharmacokinetic inequal-
ity). Despite these differences, both diuretics are efficacious in
treating patients such as those in our study although equivalent
doses correspond to a dosing ratio of furosemide to bumetanide
of 20:1 instead of the 40:1 value that occurs in patients with
normal renal function. Furthermore, we feel that the individual
dose of either diuretic should be lirjiited to that amount which
will produce the upper plateau of the dose—response curve. Our
data identifies this dose to be 160 mg of intravenous furosemide
and 6 mg to 8 mg of bumetanide.
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